Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Jubilant Cadista Pharmaceuticals, Inc.

Jubilant Cadista Pharmaceuticals, Inc. Recalls

All product recalls associated with Jubilant Cadista Pharmaceuticals, Inc..

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

303

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 2301–2320 of 4747 recalls

Valsartan Tablets (Jubilant Cadista) – Incorrect Excipient (2018)

Undeclared Allergen

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Class IIILow

FDAAug 14, 2018Nationwide• Jubilant Cadista Pharmaceuticals, Inc.

Valsartan Tablets (Jubilant Cadista) – Incorrect Excipient (2018)

Undeclared Allergen

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Class IIILow

FDAAug 14, 2018Nationwide• Jubilant Cadista Pharmaceuticals, Inc.

Valsartan Tablets 40mg (Jubilant Cadista) – incorrect excipient (2018)

1...114 115116117 118...238

Page 116 of 238Next

Undeclared Allergen

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Class IIILow

FDAAug 14, 2018Nationwide• Jubilant Cadista Pharmaceuticals, Inc.

Valsartan Tablets (Jubilant Cadista) – Incorrect Excipient (2018)

Undeclared Allergen

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Class IIILow

FDAAug 14, 2018Nationwide• Jubilant Cadista Pharmaceuticals, Inc.

Tyvaso Inhalation System (United Therapeutics) – Defective Device (2018)

Defective Delivery System: Water ingress through the lower water cup sensor of the device.

Class IIILow

FDAAug 14, 2018IL, PA• United Therapeutics Corp.

Lisinopril Tablets (Lupin) – Metal Contaminant (2018)

Presence of Foreign Substance: Product complaint was received of metal contaminant observed in one tablet.

Class IIModerate

FDAAug 13, 2018Nationwide• Lupin Pharmaceuticals Inc.

Contrave Tablets (Orexigen) – Defective Container (2018)

Defective Container: Customer complaints of punctures in the bottle.

Class IIILow

FDAAug 9, 2018Nationwide• Orexigen Therapeutics, Inc.

Diltiazem HCl Capsules (Mylan) – Stability Test Failure (2018)

Failed Impurities/Degradation Specifications: Out of specification test results obtained during routine stability testing for related compound.

Class IIILow

FDAAug 7, 2018Nationwide• Mylan Pharmaceuticals Inc.

Doxycycline Hyclate Tablets (PD-Rx) – Dissolution Failure (2018)

Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.

Class IIModerate

FDAAug 7, 2018Nationwide• PD-Rx Pharmaceuticals, Inc.

Diltiazem HCl Capsules (Mylan) – Stability Test Failure (2018)

Failed Impurities/Degradation Specifications: Out of specification test results obtained during routine stability testing for related compound.

Class IIILow

FDAAug 7, 2018Nationwide• Mylan Pharmaceuticals Inc.